The Personal Care Products Council said Peter Barton Hutt's enduring legacy will be felt throughout its organization, its ...
FDA officials said many INDs now include later-stage information that is not needed to determine whether a development ...
The first-in-class IL-33 inhibitor delivered efficacy that out-performed Dupixent in cross-trial comparisons in a broad ...
Michael Davis and Karim Mikhail had been acting directors of the drugs and biologics centers since the massive leadership ...
Topline Phase III results for DLL3-inhibiting bispecific Imdelltra plus AstraZeneca’s Imfinzi showed improved survival as a ...
The FDA management shake-up has not yet brought a change in the agency’s use, or lack thereof, of outside advisory committees ...
The US Food and Drug Administration’s next step in its long-running effort to improve data on medication use during pregnancy ...
India's Phase III trial waiver route is gaining traction as foreign and local firms pursue the pathway for oncology drugs ...
A new pathway for granting marketing authorization in Mexico to medicines already approved in Brazil is said to be a big ...
The late-stage failures within days of pelacarsen and del-desiran ‘will likely raise questions again about Novartis's due ...
Weak Q2 vaccine sales across big pharma coincided with rising US antivax sentiment and a presidential order to split the MMR ...
The company’s PVR win sets the stage for mosliciguat’s Phase III test, with the company now eyeing a bigger role in PH-ILD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results